Stockscreener 앱 받기
15.73
2.36%
-0.38
시간 외 거래:
15.73
전일 마감가:
$16.11
열려 있는:
$15.99
하루 거래량:
690.18K
Relative Volume:
0.68
시가총액:
$1.70B
수익:
$577.74M
순이익/손실:
$-149.78M
주가수익비율:
-8.457
EPS:
-1.86
순현금흐름:
$-78.21M
1주 성능:
-13.52%
1개월 성능:
-8.60%
6개월 성능:
-28.47%
1년 성능:
+27.16%
1일 변동 폭
$15.64
$16.16
1주일 범위
$15.64
$18.38
52주 변동 폭
$11.29
$24.73
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
NVCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| NVCR | 15.73 | 1.70B | 577.74M | -149.78M | -78.21M | -1.86 |
| ABT | 117.36 | 202.64B | 41.22B | 5.77B | 6.49B | 2.94 |
| SYK | 389.40 | 150.72B | 21.97B | 3.59B | 3.21B | 6.74 |
| BSX | 90.45 | 133.82B | 15.91B | 1.79B | 1.89B | 0.82 |
| MDT | 87.59 | 112.98B | 32.58B | 3.93B | 5.15B | 2.71 |
| EW | 69.89 | 40.52B | 6.60B | 4.16B | 490.10M | 2.34 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
Can Novocure's PANOVA-3 Trial Of TTFields Therapy Electrify The Stock? - RTTNews
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
NovoCure (NVCR) Shares Cross Below 200 DMA - Nasdaq
NovoCure Ltd (NVCR) Trading Down 2.79% on Nov 14 - GuruFocus.com
Baillie Gifford & Co. Sells 28,207 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
Analyze NovoCure Ltd (NASDAQ: NVCR) Before Investing. - Stocks Register
Nordwand Advisors LLC Buys 1,514,824 Shares of NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure Ltd (NVCR) Shares Up 3.63% on Nov 8 - GuruFocus.com
Novocure's oncology president sells $9,530 in shares - Investing.com India
Novocure's COO Mukund sells shares worth $2,540 By Investing.com - Investing.com Canada
Novocure's COO Mukund sells shares worth $2,540 - Investing.com India
Michal Nath Puri Sells 810 Shares of NovoCure Limited (NASDAQ:NVCR) Stock - MarketBeat
Novocure's oncology president sells $9,530 in shares By Investing.com - Investing.com Australia
NovoCure Ltd (NVCR) Shares Up 3.96% on Nov 4 - GuruFocus.com
FY2024 EPS Estimates for NovoCure Lifted by HC Wainwright - MarketBeat
Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report - Simply Wall St
NovoCure Limited (NASDAQ:NVCR) Q3 2024 Earnings Call Transcript - Insider Monkey
NovoCure shares hold Buy rating, steady price target post-earnings - Investing.com
NovoCure shares hold Buy rating, steady price target post-earnings By Investing.com - Investing.com UK
NovoCure's (NVCR) Buy Rating Reiterated at HC Wainwright - MarketBeat
NovoCure’s Strong Q3 and Leadership Changes in 2024 - Yahoo Finance
NovoCure: Q3 Earnings Snapshot - Milford Mirror
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
NovoCure Ltd (NVCR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Strategic ... - Yahoo Finance
Novocure names Christoph Brackmann as new CFO - Investing.com India
Novocure’s Q3 2024 Results Highlight Growth and Innovation - TipRanks
NovoCure (NASDAQ:NVCR) Stock Price Down 7.1%Should You Sell? - MarketBeat
Novocure Ltd earnings beat by $0.05, revenue topped estimates - Investing.com
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Novocure Appoints Christoph Brackmann as Chief Financial Officer - Yahoo Finance
Novocure Reports Third Quarter 2024 Financial Results - Yahoo Finance
Semanteon Capital Management LP Makes New Investment in NovoCure Limited (NASDAQ:NVCR) - MarketBeat
NovoCure (NVCR) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Brokerages Set NovoCure Limited (NASDAQ:NVCR) PT at $26.17 - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Shares Sold by SG Americas Securities LLC - MarketBeat
Novocure shares soar 33% as FDA approves lung cancer treatment - MSN
Leerink Partnrs Forecasts Stronger Earnings for NovoCure - MarketBeat
NovoCure scoops FDA approval on wearable for metastatic cancer treatment - Medical Device Network
Novocure's Optune Lua Receives FDA Approval For Lung Cancer Treatment - Yahoo Finance
Novocure scoops FDA approval for electric field lung cancer treatment device - Mugglehead
Deep Dive Into NovoCure Stock: Analyst Perspectives (4 Ratings) - Benzinga
NovoCure Ltd (NVCR) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
NovoCure (NASDAQ:NVCR) Shares Gap UpTime to Buy? - MarketBeat
Novocure wins FDA approval for electric field device in lung cancer - BioPharma Dive
A new trading data show NovoCure Ltd (NVCR) is showing positive returns. - SETE News
NovoCure Ltd (NVCR)’s Market Momentum: Closing Strong at 17.78, Up 10.71 - The Dwinnex
NovoCure: There Is Still More Upside (Rating Upgrade) (NASDAQ:NVCR) - Seeking Alpha
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages NovoCure Limited Investors to Secure Counsel Before Important Deadline in Securities Class ActionNVCR - AsiaOne
NovoCure stock upgraded to buy, price target set on recent FDA approval - Investing.com
NovoCure stock upgraded to buy, price target set on recent FDA approval By Investing.com - Investing.com South Africa
NovoCure (NASDAQ:NVCR) Rating Increased to Buy at HC Wainwright - MarketBeat
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.38%
0.43%
자본화:
|
볼륨(24시간):